Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
NATICK, Mass., Jan. 2, 2024 -- (Healthcare Sales & Marketing Network) -- Allorion Therapeutics ("Allorion"), a US and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune ... Biopharmaceuticals, Oncology, Licensing Allorion Therapeutics, EGFR, non-small cell lung cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Biotechnology | Cancer | Cancer & Oncology | China Health | Lung Cancer | Marketing | Non-Small Cell Lung Cancer | Pharmaceuticals